when you sell a “blood thinner” without having a antidote… expect lawsuits ?
Xarelto (rivaroxoaban) was FDA approved in 2011 as an alternative for Coumadin (warfarin), which has been the gold standard anticoagulant treatment for the past 60 years. Xarelto is one of several new-generation blood thinners, which have been promoted as easier to use than warfarin. Unfortunately, several thousand Xarelto bleeding problems have been reported since the medication was used…
According to the latest federal court census, there are almost 2,500 lawsuits filed, alleging that Xarelto caused patients to develop serious bleeding injuries. The Xarelto litigation is consolidated and centralized before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana as part of Multidistrict litigation (MDL) since December 2014… The number of Xarelto lawsuits continue to increase and be filed by individuals across the United States, alleging severe and deadly bleeding complications…
Pradaxa, the first new-generation anticoagulant to hit the market was also exposed to several thousand bleeding complication lawsuits. More than 4,000 Pradaxa injury lawsuits were filed, and Boehringer Ingleheim, the manufacturer agreed to settle the claims without any trials and paid $650 million in Pradaxa settlements, with an average of about $150,000 per claim.
(Do you see a difference in how this link is seen within this post? The link is from Pharmacist Steve’s blog, which you can now only determine by moving your mouse over the link and looking at the bottom left of your screen.)
All Things Chronic 